Abstract
PURPOSE: Studies have shown that long-term treatment with subcutaneous (SC) low-molecular-weight-heparin (LMWH) is more effective than vitamin-K-antagonist (VKA) therapy for preventing recurrent venous-thromboembolism-events (VTE) in cancer patients with VTE. The Sixth American College of Chest Physicians (ACCP) Consensus Conference (2004) recommends that patients with cancer and VTE be treated with SC-LMWH for at least six months. Our main objective was to characterize the long-term VTE treatment strategies in hospitalized cancer patients with VTE.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call